NewAmsterdam Pharma Company N.V. Research and Development Expense
NewAmsterdam Pharma Company N.V. (NAMS) reported Research and Development Expense of $41.67 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. research and development expense for the quarter ending 2026-06-30 was $41.67M, a 51.45% increase year-over-year.
- NewAmsterdam Pharma Company N.V. research and development expense for the quarter ending 2026-03-31 was $38.01M, a 15.07% decline year-over-year.
- NewAmsterdam Pharma Company N.V. research and development expense for the quarter ending 2025-12-31 was $38.59M, a 10.60% increase year-over-year.
- NewAmsterdam Pharma Company N.V. research and development expense for the quarter ending 2025-09-30 was $30.97M, a 13.25% decline year-over-year.
- NewAmsterdam Pharma Company N.V. research and development expense for fiscal 2025 was $141.83M, a 6.32% decline from fiscal 2024.
- NewAmsterdam Pharma Company N.V. research and development expense for fiscal 2024 was $151.41M, a 5.03% decline from fiscal 2023.
- NewAmsterdam Pharma Company N.V. research and development expense for fiscal 2023 was $159.42M, a 83.79% increase from fiscal 2022.
- NewAmsterdam Pharma Company N.V. research and development expense for fiscal 2022 was $86.74M, a 199.39% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.67M 10-Q · filed 2026-08-05 | $79.68M 10-Q · filed 2026-08-05 | $118.28M derived: sum of 3 quarters · filed 2026-08-05 | $149.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $38.01M 10-Q · filed 2026-05-07 | $76.60M derived: sum of 2 quarters · filed 2026-05-07 | $107.57M derived: sum of 3 quarters · filed 2026-05-07 | $135.09M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $38.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $69.56M derived: sum of 2 quarters · filed 2026-02-18 | $97.08M derived: sum of 3 quarters · filed 2026-08-05 | $141.83M 10-K · filed 2026-02-18 |
| 2025-09-30 | $30.97M 10-Q · filed 2025-11-05 | $58.49M derived: sum of 2 quarters · filed 2026-08-05 | $103.24M 10-Q · filed 2025-11-05 | $138.13M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $27.52M 10-Q · filed 2026-08-05 | $72.27M 10-Q · filed 2026-08-05 | $107.16M derived: sum of 3 quarters · filed 2026-08-05 | $142.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $44.75M 10-Q · filed 2026-05-07 | $79.65M derived: sum of 2 quarters · filed 2026-05-07 | $115.35M derived: sum of 3 quarters · filed 2026-05-07 | $153.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $34.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $70.60M derived: sum of 2 quarters · filed 2026-02-18 | $108.98M derived: sum of 3 quarters · filed 2026-02-18 | $151.41M 10-K · filed 2026-02-18 |
| 2024-09-30 | $35.70M 10-Q · filed 2025-11-05 | $74.08M derived: sum of 2 quarters · filed 2025-11-05 | $116.51M 10-Q · filed 2025-11-05 | $157.80M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-30 | $38.38M 10-Q · filed 2025-08-06 | $80.81M 10-Q · filed 2025-08-06 | $122.10M derived: sum of 3 quarters · filed 2026-02-18 | $165.47M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-31 | $42.43M 10-Q · filed 2025-05-08 | $83.72M derived: sum of 2 quarters · filed 2026-02-18 | $127.09M derived: sum of 3 quarters · filed 2026-02-18 | $161.43M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-31 | $41.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $84.66M derived: sum of 2 quarters · filed 2026-02-18 | $119.00M derived: sum of 3 quarters · filed 2026-02-18 | $159.42M 10-K · filed 2026-02-18 |
| 2023-09-30 | $43.37M 10-Q · filed 2024-11-06 | $77.71M derived: sum of 2 quarters · filed 2024-11-06 | $118.13M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $34.34M 10-Q · filed 2024-08-07 | $74.76M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $40.42M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $86.74M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $28.97M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |